Despite these controversial issues, the encouraging results using lubiprostone in CF patients [18] and with CF cells and tissues [2,17], made it reasonable to test the hypothesis that lubiprostone would ameliorate the intestinal phenotype in the Cftr knockout mouse. The gene discussed is CFTR; the disease is cystic fibrosis.